Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, it is still a bit surprising, since the pharmaceutical giant is one of the ...

The renowned medical device company has a market capitalization of $2.31 billion. Tandem Diabetes projects a growth rate of 28.6% for 2025 earnings compared with 18.7% for the S&P 500. TNDM delivered ...

In the near and long term, the company aims ... slim X2 became compatible with Eli Lilly and Company’s Lyumjev — an ultra-rapid-acting insulin in the European Union. In addition, the company ...

Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type ...

Both companies have a dominant position in their industry and a solid financial position, but Eli Lilly ... a generic insulin. At most it can sell a biosimilar, but that is a long and winding ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provi ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind schedule ...

The pharmaceutical company Novo Nordisk has products sold under the Novolin brand name, and Eli Lilly ... (short-acting), NPH (intermediate-acting), or premixed NPH/regular insulin without a ...

Gov. Gavin Newsom’s ambitious plan to produce a cheap, generic insulin for the 3.2 million Californians with diabetes is behind the schedule he announced and unlikely to make it to market for ...